Abstract:Abstract Forkhead box protein M1 (FOXM1) is often overexpressed in human cancers and strongly associated with therapy resistance and less good patient survival. The chemotherapy options for patients with the most aggressive types of solid cancers remain very limited because of the acquired drug resistance, making the therapy less effective. NPM1 mutation through the inactivation of FOXM1 via FOXM1 relocalization to the cytoplasm confers more favorable treatment outcomes for AML patients, confirming FOXM1 as a crucial target to overcome drug resistance. Pharmacological inhibition of FOXM1 could be a promising approach to sensitize therapy-resistant cancers. Here, we explore a novel FOXM1 inhibitor STL001, a first-generation modification drug of our previously reported FOXM1 inhibitor STL427944. STL001 preserves the mode of action of the STL427944; however, STL001 is up to 50 times more efficient in reducing FOXM1 activity in a variety of solid cancers. The most conventional cancer therapies studied here induce FOXM1 overexpression in solid cancers. The therapy-induced FOXM1 overexpression may explain the failure or reduced efficacy of these drugs in cancer patients. Interestingly, STL001 increased the sensitivity of cancer cells to conventional cancer therapies by suppressing both the high-endogenous and drug-induced FOXM1. Notably, STL001 does not provide further sensitization to FOXM1-KD cancer cells, suggesting that the sensitization effect is conveyed specifically through FOXM1 suppression. RNA-seq and gene set enrichment studies revealed prominent suppression of FOXM1-dependent pathways and gene ontologies. Also, gene regulation by STL001 showed extensive overlap with FOXM1-KD, suggesting a high selectivity of STL001 toward the FOXM1 regulatory network. A completely new activity of FOXM1, mediated through steroid/cholesterol biosynthetic process and protein secretion in cancer cells was also detected. Collectively, STL001 offers intriguing translational opportunities as combination therapies targeting FOXM1 activity in a variety of human cancers driven by FOXM1.

Development of an Interfering Peptide M1-20 with Potent Anti-Cancer Effects by Targeting FOXM1.

The Development of an Anti-Cancer Peptide M1-21 Targeting Transcription Factor FOXM1

The cell-penetrating FOXM1 N-terminus (M1-138) demonstrates potent inhibitory effects on cancer cells by targeting FOXM1 and FOXM1-interacting factor SMAD3

FoxM1 as a novel therapeutic target for cancer drug therapy.

The Antitumor Peptide M1-20 Induced the Degradation of CDK1 Through CUL4-DDB1-DCAF1-involved Ubiquitination.

Peptide-based PROTAC degrader of FOXM1 suppresses cancer and decreases GLUT1 and PD-L1 expression

Expression and Selection of Human Foxm1c Binding Peptides and Their Inhibitions on MCF7 Cancer Cells

FOXM1 Inhibition Enhances the Therapeutic Outcome of Lung Cancer Immunotherapy by Modulating PD‐L1 Expression and Cell Proliferation

Targeting of the FOXM1 Oncoprotein by E3 Ligase-Assisted Degradation

Novel FOXM1 inhibitor STL001 sensitizes human cancers to a broad-spectrum of cancer therapies

Inhibition of Cyclin-Dependent Kinase Phosphorylation of Foxo1 and Prostate Cancer Cell Growth by A Peptide Derived from Foxo1

Inhibition of Foxm1 Transcription Factor Suppresses Cell Proliferation and Tumor Growth of Breast Cancer

FOXM1 promotes the progression of non-small cell lung cancer by inhibiting miR-509-5p expression via binding to the miR-509-5p promoter region

Retraction Note To: FoxM1 Down-Regulation Leads to Inhibition of Proliferation, Migration and Invasion of Breast Cancer Cells Through the Modulation of Extra-Cellular Matrix Degrading Factors

Peptide Blockers of PD-1-PD-L1 Interaction Reinvigorate PD-1-Suppressed T Cells and Curb Tumor Growth in Mice

Biosynthesis of Multifunctional Transformable Peptides for Downregulation of PD-L1

Design and Evaluation of Α-Helix-based Peptide Inhibitors for Blocking PD-1/PD-L1 Interaction.

Develop a PD-1-blockade Peptide to Reinvigorate T-cell Activity and Inhibit Tumor Progress.

Small peptides elicit anti-tumor effects in CT26 model through blocking PD-L1/PD-1 (TUM2P.900)

Peptide blocking of PD-1/PD-L1 interaction for cancer immunotherapy.

Development of small molecule inhibitors targeting PBX1 transcription signaling as a novel cancer therapeutic strategy